Risk factors and clinical responses of pneumonia patients with colistin-resistant Acinetobacter baumannii-calcoaceticus

被引:0
|
作者
Hande Aydemir [1 ]
Hande Idil Tuz [1 ]
Nihal Piskin [1 ]
Guven Celebi [1 ]
Canan Kulah [2 ]
Furuzan Kokturk [3 ]
机构
[1] Department of Infectious Diseases and Clinical Microbiology,Zonguldak Bulent Ecevit University,Faculty of Medicine
[2] Department of Microbiology,Zonguldak Bulent Ecevit University,Faculty of Medicine
[3] Department of Biostatistics,Zonguldak Bulent Ecevit University,Faculty of Medicine
关键词
Acinetobacter baumannii; Colistin; Ventilator-associated pneumonia;
D O I
暂无
中图分类号
R563.1 [肺炎];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Nosocomial infections with carbapenem-resistant Acinetobacter baumanniicalcoaceticus complex(ABC) strains are great problem for intensive care units.ABC strains can develop resistance to all the antibiotics available. Carbapenem resistance is common and colistin resistance is rare in our country. Knowing the risk factors for colistin resistance is important since colistin seems to be the only remaining therapeutic option for the patients with pneumonia due to extensively drug resistant ABC for our country.AIM To investigate the comparison of clinical responses and outcomes between pneumonia patients with colistin-susceptible and-resistant Acinetobacter sp.Strains.METHODS During the study period, 108 patients with pneumonia due to colistin-susceptible strains and 16 patients with colistin-resistant strains were included retrospectively. Continuous variables were compared with the Mann-Whitney U test, and categorical variables were compared using Pearson’s chi-square test or Fisher’s Exact chi-square test for two groups. A binary logistic regression model was developed to identify the potential independent factors associated with colistin resistance in patients with colistin-resistant strains.RESULTS High Acute Physiology and Chronic Health Evaluation II scores(OR = 1.9,95%CI: 1.4-2.7; P < 0.001) and prior receipt of teicoplanin(OR = 8.1, 95%CI: 1.0-63.3; P = 0.045) were found to be independent risk factors for infection with colistin-resistant Acinetobacter sp. Different combinations of antibiotics including colistin, meropenem, ampicillin/sulbactam, amikacin and trimethoprim/sulfamethoxazole were used for the treatment of patients with colistin-resistant strains. Although the median duration of microbiological cure(P < 0.001) was longer in the colistin-resistant group, clinical(P = 0.703),laboratory(P = 0.277), radiological(P = 0.551), microbiological response(P =1.000) and infection related mortality rates(P = 0.603) did not differ between the two groups. Among the patients with infections due to colistin-resistant strains,seven were treated with antibiotic combinations that included sulbactam. Clinical(6/7) and microbiological(5/7) response rates were quite high in these patients.CONCLUSION The optimal therapy regimen is unclear for colistin-resistant Acinetobacter sp.infections. Although combinations with sulbactam seems to be more effective in our study patients, data supporting the usefulness of combinations with sulbactam is very limited.
引用
收藏
页码:1111 / 1121
页数:11
相关论文
共 50 条
  • [31] Quercetin: Synergistic Interaction with Antibiotics against Colistin-Resistant Acinetobacter baumannii
    Kose, Elif Odabas
    Ozyurt, Ozlem Koyuncu
    Bilmen, Sureyya
    Er, Hakan
    Kilit, Cansu
    Aydemir, Esra
    ANTIBIOTICS-BASEL, 2023, 12 (04):
  • [32] Activities of Vancomycin-Containing Regimens against Colistin-Resistant Acinetobacter baumannii Clinical Strains
    O'Hara, Jessica A.
    Ambe, Lauretta A.
    Casella, Leila G.
    Townsend, Bethany M.
    Pelletier, Mark R.
    Ernst, Robert K.
    Shanks, Robert M. Q.
    Doi, Yohei
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (05) : 2103 - 2108
  • [33] EFFECTIVENESS OF COLISTIN WITH RIFAMPICIN AND MEROPENEM AGAINST COLISTIN-RESISTANT ACINETOBACTER BAUMANNII STRAINS: AN IN VITRO STUDY
    Mosca, Adriana
    Dalfino, Lidia
    Romanelli, Federica
    Stolfa, Stefania
    Del Prete, Raffaele
    Santacroce, Luigi
    PHARMACOPHORE, 2020, 11 (02): : 1 - 6
  • [34] The molecular characterization of colistin-resistant isolates of Acinetobacter baumannii from patients at intensive care units
    Farajnia, Safar
    Lotfi, Fariba
    Dehnad, Alireza
    Shojaie, Maryam
    Raisi, Roya
    Rahbarnia, Leila
    Bazmani, Ahad
    Naghili, Behrooz
    Shiry, Samaneh
    IRANIAN JOURNAL OF MICROBIOLOGY, 2022, 14 (03) : 319 - 327
  • [35] Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections
    Shields, Ryan K.
    Paterson, David L.
    Tamma, Pranita D.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 : S179 - S193
  • [36] Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex
    Garcia, Rebeca Carvalho Lacerda
    Rodrigues, Rodrigo Douglas
    Garcia, Ester Carvalho Lacerda
    Rigatto, Maria Helena
    ANTIBIOTICS-BASEL, 2023, 12 (08):
  • [37] Epidemiology of colistin-resistant, carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Croatia
    D'Onofrio, Valentino
    Conzemius, Rick
    Varda-Brkic, Dijana
    Bogdan, Maja
    Grisold, Andrea
    Gyssens, Inge C.
    Bedenic, Branka
    Barisic, Ivan
    INFECTION GENETICS AND EVOLUTION, 2020, 81
  • [38] Efficacy of isolated bacteriophage against biofilm embedded colistin-resistant Acinetobacter baumannii
    Ebrahimi, Saeedeh
    Sisakhtpour, Behnam
    Mirzaei, Arezoo
    Karbasizadeh, Vajihe
    Moghim, Sharareh
    GENE REPORTS, 2021, 22
  • [39] Intensified Infection Control Measures to Minimize the Spread of Colistin-Resistant Acinetobacter baumannii
    Apisaranthanarak, Anucha
    Rujanavech, Sassinuch
    Luxamesathaporn, Pornpong
    Mundy, Linda M.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2013, 34 (04): : 445 - 447
  • [40] In Vivo Fitness Adaptations of Colistin-Resistant Acinetobacter baumannii Isolates to Oxidative Stress
    Jones, Crystal L.
    Singh, Shweta S.
    Alamneh, Yonas
    Casella, Leila G.
    Ernst, Robert K.
    Lesho, Emil P.
    Waterman, Paige E.
    Zurawski, Daniel V.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (03)